nach oben

Erschienen in:

09.11.2017 | Original paper

Determinants of prolactin in postmenopausal Chinese women in Singapore

verfasst von: Tiffany A. Katz, Anna H. Wu, Frank Z. Stanczyk, Renwei Wang, Woon-Puay Koh, Jian-Min Yuan, Steffi Oesterreich, Lesley M. Butler

Erschienen in: Cancer Causes & Control | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Mechanistic and observational data together support a role for prolactin in breast cancer development. Determinants of prolactin in Asian populations have not been meaningfully explored, despite the lower risk of breast cancer in Asian populations.

Methods

Determinants of plasma prolactin were evaluated in 442 postmenopausal women enrolled in the Singapore Chinese Health Study, a population-based prospective cohort study. At baseline all cohort members completed an in-person interview that elicited information on diet, menstrual and reproductive history, and lifestyle factors. One year after cohort initiation we began collecting blood samples. Quantified were plasma concentrations of prolactin, estrone, estradiol, testosterone, androstenedione, and sex hormone-binding globulin (SHBG). Analysis of covariance method was used for statistical analyses with age at blood draw, time since last meal, and time at blood draw as covariates.

Results

Mean prolactin levels were 25.1% lower with older age at menarche (p value = 0.001), and 27.6% higher with greater years between menarche and menopause (p value = 0.009). Prolactin levels were also positively associated with increased sleep duration (p value = 0.005). The independent determinants of prolactin were years from menarche to menopause, hours of sleep, and the plasma hormones estrone and SHBG (all p values < 0.01).

Conclusion

The role of prolactin in breast cancer development may involve reproductive and lifestyle factors, such as a longer duration of menstrual cycling and sleep patterns.

Nur mit Berechtigung zugänglich

Perks CM, Keith AJ, Goodhew KL, Savage PB, Winters ZE, Holly JM (2004) Prolactin acts as a potent survival factor for human breast cancer cell lines. Br J Cancer 91(2):305–311. https://doi.org/10.1038/sj.bjc.6601947 PubMedPubMedCentralCrossRef

Touraine P, Martini JF, Zafrani B, Durand JC, Labaille F, Malet C, Nicolas A, Trivin C, Postel-Vinay MC, Kuttenn F, Kelly PA (1998) Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues. J Clin Endocrinol Metab 83(2):667–674. https://doi.org/10.1210/jcem.83.2.4564 PubMedCrossRef

Rose-Hellekant TA, Arendt LM, Schroeder MD, Gilchrist K, Sandgren EP, Schuler LA (2003) Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice. Oncogene 22(30):4664–4674. https://doi.org/10.1038/sj.onc.1206619 PubMedPubMedCentralCrossRef

Wennbo H, Gebre-Medhin M, Gritli-Linde A, Ohlsson C, Isaksson OG, Tornell J (1997) Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice. J Clin Invest 100(11):2744–2751. https://doi.org/10.1172/JCI119820 PubMedPubMedCentralCrossRef

Arendt LM, Rugowski DE, Grafwallner-Huseth TA, Garcia-Barchino MJ, Rui H, Schuler LA (2011) Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer. Breast Cancer Res 13(1):R11. https://doi.org/10.1186/bcr2819 PubMedPubMedCentralCrossRef

Yang N, Liu C, Peck AR, Girondo MA, Yanac AF, Tran TH, Utama FE, Tanaka T, Freydin B, Chervoneva I, Hyslop T, Kovatich AJ, Hooke JA, Shriver CD, Rui H (2013) Prolactin-Stat5 signaling in breast cancer is potently disrupted by acidosis within the tumor microenvironment. Breast Cancer Res 15(5):R73. https://doi.org/10.1186/bcr3467 PubMedPubMedCentralCrossRef

Tikk K, Sookthai D, Johnson T, Rinaldi S, Romieu I, Tjonneland A, Olsen A, Overvad K, Clavel-Chapelon F, Baglietto L, Boeing H, Trichopoulou A, Lagiou P, Trichopoulos D, Palli D, Pala V, Tumino R, Rosso S, Panico S, Agudo A, Menendez V, Sanchez MJ, Amiano P, Huerta Castano JM, Ardanaz E, Bueno-de-Mesquita HB, Monninkhof E, Onland-Moret C, Andersson A, Sund M, Weiderpass E, Khaw KT, Key TJ, Travis RC, Gunter MJ, Riboli E, Dossus L, Kaaks R (2014) Circulating prolactin and breast cancer risk among pre- and postmenopausal women in the EPIC cohort. Annals of oncology: official journal of the European Society for Medical Oncology. ESMO 25(7):1422–1428. https://doi.org/10.1093/annonc/mdu150

Tworoger SS, Eliassen AH, Zhang X, Qian J, Sluss PM, Rosner BA, Hankinson SE (2013) A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development. Cancer Res 73(15):4810–4819. https://doi.org/10.1158/0008-5472.CAN-13-0665 PubMedPubMedCentralCrossRef

Eliassen AH, Tworoger SS, Hankinson SE (2007) Reproductive factors and family history of breast cancer in relation to plasma prolactin levels in premenopausal and postmenopausal women. Int J Cancer 120(7):1536–1541. https://doi.org/10.1002/ijc.22482 PubMedCrossRef

10.

Ingram DM, Nottage EM, Roberts AN (1990) Prolactin and breast cancer risk. Med J Aust 153(8):469–473PubMed

11.

Tikk K, Sookthai D, Johnson T, Dossus L, Clavel-Chapelon F, Tjonneland A, Olsen A, Overvad K, Baglietto L, Rinaldi S, Romieu I, Boeing H, Trichopoulou A, Lagiou P, Trichopoulos D, Masala G, Agnoli C, Tumino R, Sacerdote C, Mattiello A, Buckland G, Sanchez S, Molina-Montes E, Amiano P, Castano JM, Barricarte A, Bueno-de-Mesquita HB, Monninkhof EM, Onland-Moret NC, Idahl A, Lundin E, Weiderpass E, Lund E, Waaseth M, Khaw KT, Key TJ, Travis RC, Gunter MJ, Riboli E, Kaaks R (2014) Prolactin determinants in healthy women: A large cross-sectional study within the EPIC cohort. Cancer Epidemiol Biomark Prev 23(11):2532–2542. https://doi.org/10.1158/1055-9965.EPI-14-0613 CrossRef

12.

Tworoger SS, Rice MS, Rosner BA, Feeney YB, Clevenger CV, Hankinson SE (2015) Bioactive prolactin levels and risk of breast cancer: a nested case-control study. Cancer Epidemiol Biomark Prev 24(1):73–80. https://doi.org/10.1158/1055-9965.EPI-14-0896 CrossRef

13.

Faupel-Badger JM, Sherman ME, Garcia-Closas M, Gaudet MM, Falk RT, Andaya A, Pfeiffer RM, Yang XR, Lissowska J, Brinton LA, Peplonska B, Vonderhaar BK, Figueroa JD (2010) Prolactin serum levels and breast cancer: relationships with risk factors and tumour characteristics among pre- and postmenopausal women in a population-based case-control study from Poland. Br J Cancer 103(7):1097–1102. https://doi.org/10.1038/sj.bjc.6605844 PubMedPubMedCentralCrossRef

14.

McTiernan A, Wu L, Chen C, Chlebowski R, Mossavar-Rahmani Y, Modugno F, Perri MG, Stanczyk FZ, Van Horn L, Wang CY, Women’s Health Initiative I (2006) Relation of BMI and physical activity to sex hormones in postmenopausal women. Obesity 14(9):1662–1677. https://doi.org/10.1038/oby.2006.191 PubMedCrossRef

15.

Nagata C, Wada K, Nakamura K, Hayashi M, Takeda N, Yasuda K (2011) Associations of body size and reproductive factors with circulating levels of sex hormones and prolactin in premenopausal Japanese women. Cancer Causes Control 22(4):581–588. https://doi.org/10.1007/s10552-011-9731-x PubMedCrossRef

16.

Brown BD, Thomas W, Hutchins A, Martini MC, Slavin JL (2002) Types of dietary fat and soy minimally affect hormones and biomarkers associated with breast cancer risk in premenopausal women. Nutr Cancer 43(1):22–30. https://doi.org/10.1207/S15327914NC431_2 PubMedCrossRef

17.

Hirko KA, Spiegelman D, Barnett JB, Cho E, Willett WC, Hankinson SE, Eliassen AH (2016) Dietary patterns and plasma sex hormones, prolactin and sex hormone-binding globulin in premenopausal women. Cancer Epidemiol Biomark Prev. https://doi.org/10.1158/1055-9965.EPI-15-1019

18.

Tsuji M, Tamai Y, Wada K, Nakamura K, Hayashi M, Takeda N, Yasuda K, Nagata C (2012) Associations of intakes of fat, dietary fiber, soy isoflavones, and alcohol with levels of sex hormones and prolactin in premenopausal Japanese women. Cancer Causes Control 23(5):683–689. https://doi.org/10.1007/s10552-012-9935-8 PubMedCrossRef

19.

Bray F, McCarron P, Parkin DM (2004) The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 6(6):229–239. https://doi.org/10.1186/bcr932 PubMedPubMedCentralCrossRef

20.

Global Burden of Disease Cancer C, Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R, Wolfe C, Hamadeh RR, Moore A, Werdecker A, Gessner BD, Te Ao B, McMahon B, Karimkhani C, Yu C, Cooke GS, Schwebel DC, Carpenter DO, Pereira DM, Nash D, Kazi DS, De Leo D, Plass D, Ukwaja KN, Thurston GD, Yun Jin K, Simard EP, Mills E, Park EK, Catala-Lopez F, deVeber G, Gotay C, Khan G, Hosgood HD, 3rd, Santos IS, Leasher JL, Singh J, Leigh J, Jonas JB, Sanabria J, Beardsley J, Jacobsen KH, Takahashi K, Franklin RC, Ronfani L, Montico M, Naldi L, Tonelli M, Geleijnse J, Petzold M, Shrime MG, Younis M, Yonemoto N, Breitborde N, Yip P, Pourmalek F, Lotufo PA, Esteghamati A, Hankey GJ, Ali R, Lunevicius R, Malekzadeh R, Dellavalle R, Weintraub R, Lucas R, Hay R, Rojas-Rueda D, Westerman R, Sepanlou SG, Nolte S, Patten S, Weichenthal S, Abera SF, Fereshtehnejad SM, Shiue I, Driscoll T, Vasankari T, Alsharif U, Rahimi-Movaghar V, Vlassov VV, Marcenes WS, Mekonnen W, Melaku YA, Yano Y, Artaman A, Campos I, MacLachlan J, Mueller U, Kim D, Trillini M, Eshrati B, Williams HC, Shibuya K, Dandona R, Murthy K, Cowie B, Amare AT, Antonio CA, Castaneda-Orjuela C, van Gool CH, Violante F, Oh IH, Deribe K, Soreide K, Knibbs L, Kereselidze M, Green M, Cardenas R, Roy N, Tillmann T, Li Y, Krueger H, Monasta L, Dey S, Sheikhbahaei S, Hafezi-Nejad N, Kumar GA, Sreeramareddy CT, Dandona L, Wang H, Vollset SE, Mokdad A, Salomon JA, Lozano R, Vos T, Forouzanfar M, Lopez A, Murray C, Naghavi M (2015) The Global Burden of Cancer 2013. JAMA Oncol 1(4):505–527. https://doi.org/10.1001/jamaoncol.2015.0735 CrossRef

21.

Yuan JM, Stram DO, Arakawa K, Lee HP, Yu MC (2003) Dietary cryptoxanthin and reduced risk of lung cancer: the Singapore Chinese Health Study. Cancer Epidemiol Biomark Prev 12(9):890–898

22.

Hankin JH, Stram DO, Arakawa K, Park S, Low SH, Lee HP, Yu MC (2001) Singapore Chinese Health Study: development, validation, and calibration of the quantitative food frequency questionnaire. Nutr Cancer 39(2):187–195PubMedCrossRef

23.

Wu AH, Arakawa K, Stanczyk FZ, Van Den Berg D, Koh WP, Yu MC (2005) Tea and circulating estrogen levels in postmenopausal Chinese women in Singapore. Carcinogenesis 26(5):976–980. https://doi.org/10.1093/carcin/bgi028 PubMedCrossRef

24.

Reding KW, Lampe JW, Wang CY, Stanczyk FZ, Ulrich CM, Xiao L, Duggan CR, McTiernan A (2011) A 12-month moderate-intensity exercise intervention does not alter serum prolactin concentrations. Cancer Epidemiol 35(6):569–573. https://doi.org/10.1016/j.canep.2011.01.006 PubMedPubMedCentralCrossRef

25.

Goebelsmann U, Horton R, Mestman JH, Arce JJ, Nagata Y, Nakamura RM, Thorneycroft IH, Mishell DR Jr (1973) Male pseudohermaphroditism due to testicular 17-hydroxysteroid dehydrogenase deficiency. J Clin Endocrinol Metab 36(5):867–879PubMedCrossRef

26.

Stanczyk FZ, Shoupe D, Nunez V, Macias-Gonzales P, Vijod MA, Lobo RA (1988) A randomized comparison of nonoral estradiol delivery in postmenopausal women. Am J Obstet Gynecol 159(6):1540–1546PubMedCrossRef

27.

Wu AH, Stanczyk FZ, Seow A, Lee HP, Yu MC (2002) Soy intake and other lifestyle determinants of serum estrogen levels among postmenopausal Chinese women in Singapore. Cancer Epidemiol Biomark Prev 11 (9):844–851

28.

Sodergard R, Backstrom T, Shanbhag V, Carstensen H (1982) Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem 16(6):801–810PubMedCrossRef

29.

Rinaldi S, Dechaud H, Toniolo P, Kaaks R (2002) Reliability and validity of direct radioimmunoassays for measurement of postmenopausal serum androgens and estrogens. IARC Sci Publ 156:323–325PubMed

30.

Arnal PJ, Drogou C, Sauvet F, Regnauld J, Dispersyn G, Faraut B, Millet GY, Leger D, Gomez-Merino D, Chennaoui M (2016) Effect of sleep extension on the subsequent testosterone, cortisol and prolactin responses to total sleep deprivation and recovery. J Neuroendocrinol 28(2):12346. https://doi.org/10.1111/jne.12346 PubMedCrossRef

31.

Baumgartner A, Graf KJ, Kurten I, Meinhold H, Scholz P (1990) Neuroendocrinological investigations during sleep deprivation in depression. I. Early morning levels of thyrotropin, TH, cortisol, prolactin, LH, FSH, estradiol, and testosterone. Biol Psychiatry 28(7):556–568PubMedCrossRef

32.

Ebert D, Kaschka W, Stegbauer P, Schrell U (1993) Prolactin response to sulpiride before and after sleep deprivation in depression. Biol Psychiatry 33(8–9):666–669PubMedCrossRef

33.

Parry BL, Hauger R, LeVeau B, Mostofi N, Cover H, Clopton P, Gillin JC (1996) Circadian rhythms of prolactin and thyroid-stimulating hormone during the menstrual cycle and early versus late sleep deprivation in premenstrual dysphoric disorder. Psychiatry Res 62(2):147–160PubMedCrossRef

34.

Kuhs H, Farber D, Tolle R (1996) Serum prolactin, growth hormone, total corticoids, thyroid hormones and thyrotropine during serial therapeutic sleep deprivation. Biol Psychiatry 39(10):857–864. https://doi.org/10.1016/0006-3223(95)00240-5 PubMedCrossRef

35.

Baumgartner A, Riemann D, Berger M (1990) Neuroendocrinological investigations during sleep deprivation in depression. II. Longitudinal measurement of thyrotropin, TH, cortisol, prolactin, GH, and LH during sleep and sleep deprivation. Biol Psychiatry 28(7):569–587PubMedCrossRef

36.

He C, Anand ST, Ebell MH, Vena JE, Robb SW (2015) Circadian disrupting exposures and breast cancer risk: a meta-analysis. Int Arch Occup Environ Health 88(5):533–547. https://doi.org/10.1007/s00420-014-0986-x PubMedCrossRef

37.

Lin X, Chen W, Wei F, Ying M, Wei W, Xie X (2015) Night-shift work increases morbidity of breast cancer and all-cause mortality: a meta-analysis of 16 prospective cohort studies. Sleep Med 16(11):1381–1387. https://doi.org/10.1016/j.sleep.2015.02.543 PubMedCrossRef

38.

Hurley S, Goldberg D, Bernstein L, Reynolds P (2015) Sleep duration and cancer risk in women. Cancer Causes Control 26(7):1037–1045. https://doi.org/10.1007/s10552-015-0579-3

39.

McElroy JA, Newcomb PA, Titus-Ernstoff L, Trentham-Dietz A, Hampton JM, Egan KM (2006) Duration of sleep and breast cancer risk in a large population-based case-control study. J Sleep Res 15(3):241–249. https://doi.org/10.1111/j.1365-2869.2006.00523.x PubMedCrossRef

40.

Pinheiro SP, Schernhammer ES, Tworoger SS, Michels KB (2006) A prospective study on habitual duration of sleep and incidence of breast cancer in a large cohort of women. Cancer Res 66(10):5521–5525. https://doi.org/10.1158/0008-5472.CAN-05-4652 PubMedCrossRef

41.

Vogtmann E, Levitan EB, Hale L, Shikany JM, Shah NA, Endeshaw Y, Lewis CE, Manson JE, Chlebowski RT (2013) Association between sleep and breast cancer incidence among postmenopausal women in the Women’s Health Initiative. Sleep 36(10):1437–1444. https://doi.org/10.5665/sleep.3032 PubMedPubMedCentralCrossRef

42.

Girschik J, Heyworth J, Fritschi L (2013) Self-reported sleep duration, sleep quality, and breast cancer risk in a population-based case-control study. Am J Epidemiol 177(4):316–327. https://doi.org/10.1093/aje/kws422 PubMedCrossRef

43.

Qian X, Brinton LA, Schairer C, Matthews CE (2015) Sleep duration and breast cancer risk in the Breast Cancer Detection Demonstration Project follow-up cohort. Br J Cancer 112(3):567–571. https://doi.org/10.1038/bjc.2014.600 PubMedCrossRef

44.

Verkasalo PK, Lillberg K, Stevens RG, Hublin C, Partinen M, Koskenvuo M, Kaprio J (2005) Sleep duration and breast cancer: a prospective cohort study. Cancer Res 65(20):9595–9600. https://doi.org/10.1158/0008-5472.CAN-05-2138 PubMedCrossRef

45.

Wu AH, Stanczyk FZ, Wang R, Koh WP, Yuan JM, Yu MC (2013) Sleep duration, spot urinary 6-sulfatoxymelatonin levels and risk of breast cancer among Chinese women in Singapore. Int J Cancer 132(4):891–896. https://doi.org/10.1002/ijc.27653 PubMedCrossRef

46.

Wu AH, Wang R, Koh WP, Stanczyk FZ, Lee HP, Yu MC (2008) Sleep duration, melatonin and breast cancer among Chinese women in Singapore. Carcinogenesis 29(6):1244–1248. https://doi.org/10.1093/carcin/bgn100 PubMedPubMedCentralCrossRef

47.

Roelfsema F, Pijl H, Keenan DM, Veldhuis JD (2012) Prolactin secretion in healthy adults is determined by gender, age and body mass index. PLoS ONE 7(2):e31305. https://doi.org/10.1371/journal.pone.0031305 PubMedPubMedCentralCrossRef

48.

von Treuer K, Norman TR, Armstrong SM (1996) Overnight human plasma melatonin, cortisol, prolactin, TSH, under conditions of normal sleep, sleep deprivation, and sleep recovery. J Pineal Res 20(1):7–14CrossRef

49.

Chavez-MacGregor M, van Gils CH, van der Schouw YT, Monninkhof E, van Noord PA, Peeters PH (2008) Lifetime cumulative number of menstrual cycles and serum sex hormone levels in postmenopausal women. Breast Cancer Res Treat 108(1):101–112. https://doi.org/10.1007/s10549-007-9574-z PubMedCrossRef

50.

Endogenous H, Breast Cancer Collaborative G, Key TJ, Appleby PN, Reeves GK, Roddam AW, Helzlsouer KJ, Alberg AJ, Rollison DE, Dorgan JF, Brinton LA, Overvad K, Kaaks R, Trichopoulou A, Clavel-Chapelon F, Panico S, Duell EJ, Peeters PH, Rinaldi S, Fentiman IS, Dowsett M, Manjer J, Lenner P, Hallmans G, Baglietto L, English DR, Giles GG, Hopper JL, Severi G, Morris HA, Hankinson SE, Tworoger SS, Koenig K, Zeleniuch-Jacquotte A, Arslan AA, Toniolo P, Shore RE, Krogh V, Micheli A, Berrino F, Barrett-Connor E, Laughlin GA, Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE, Cauley JA, Lui LY, Cummings SR, Gunter MJ, Rohan TE, Strickler HD (2011) Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer 105(5):709–722. https://doi.org/10.1038/bjc.2011.254 CrossRef

51.

Chavez-MacGregor M, Elias SG, Onland-Moret NC, van der Schouw YT, Van Gils CH, Monninkhof E, Grobbee DE, Peeters PH (2005) Postmenopausal breast cancer risk and cumulative number of menstrual cycles. Cancer Epidemiol Biomark Prev 14(4):799–804. https://doi.org/10.1158/1055-9965.EPI-04-0465 CrossRef

52.

Clavel-Chapelon F, Group EN (2002) Cumulative number of menstrual cycles and breast cancer risk: results from the E3N cohort study of French women. Cancer Causes Control 13(9):831–838PubMedPubMedCentralCrossRef

53.

Wu AH, Vigen C, Lee E, Tseng CC, Butler LM (2016) Traditional Breast Cancer Risk Factors in Filipina Americans Compared with Chinese and Japanese Americans in Los Angeles County. Cancer Epidemiol Biomark Prev 25(12):1572–1586. https://doi.org/10.1158/1055-9965.EPI-16-0203 CrossRef

54.

Wang DY, de Stavola BL, Bulbrook RD, Allen DS, Kwa HG, Verstraeten AA, Moore JW, Fentiman IS, Hayward JL, Gravelle IH (1988) The permanent effect of reproductive events on blood prolactin levels and its relation to breast cancer risk: a population study of postmenopausal women. Eur J Cancer Clin Oncol 24(7):1225–1231PubMedCrossRef

55.

Crowley WR (2015) Neuroendocrine regulation of lactation and milk production. Compr Physiol 5(1):255–291. https://doi.org/10.1002/cphy.c140029 PubMed

56.

Chua L, Win AM (2013) Prevalence of breastfeeding in Singapore. Stat Singap Newsl. https://www.singstat.gov.sg/docs/default-source/default-documentlibrary/publications/newsletter/archive/ssnsep2013.pdf

57.

Pasqualini JR (2004) The selective estrogen enzyme modulators in breast cancer: a review. Biochim Biophys Acta 1654(2):123–143. https://doi.org/10.1016/j.bbcan.2004.03.001 PubMed

58.

Tworoger SS, Zhang X, Eliassen AH, Qian J, Colditz GA, Willett WC, Rosner BA, Kraft P, Hankinson SE (2014) Inclusion of endogenous hormone levels in risk prediction models of postmenopausal breast cancer. J Clin Oncol 32(28):3111–3117. https://doi.org/10.1200/JCO.2014.56.1068 PubMedPubMedCentralCrossRef

59.

Duggan C, Stanczyk F, Campbell K, Neuhouser ML, Baumgartner RN, Baumgartner KB, Bernstein L, Ballard R, McTiernan A (2016) Associations of sex steroid hormones with mortality in women with breast cancer. Breast Cancer Res Treat 155(3):559–567. https://doi.org/10.1007/s10549-016-3704-4 PubMedCrossRef

60.

Fourkala EO, Blyuss O, Field H, Gunu R, Ryan A, Barth J, Jacobs I, Zaikin A, Dawnay A, Menon U (2016) Sex hormone measurements using mass spectrometry and sensitive extraction radioimmunoassay and risk of estrogen receptor negative and positive breast cancer: case control study in UK Collaborative Cancer Trial of Ovarian Cancer Screening (UKCTOCS). Steroids 110:62–69. https://doi.org/10.1016/j.steroids.2016.04.003 PubMedCrossRef

61.

Husing A, Fortner RT, Kuhn T, Overvad K, Tjonneland A, Olsen A, Boutron-Ruault MC, Severi G, Fournier A, Boeing H, Trichopoulou A, Benetou V, Orfanos P, Masala G, Pala V, Tumino R, Fasanelli F, Panico S, Bueno de Mesquita HB, Peeters PH, van Gills CH, Quiros JR, Agudo A, Sanchez MJ, Chirlaque MD, Barricarte A, Amiano P, Khaw KT, Travis RC, Dossus L, Li K, Ferrari P, Merritt MA, Tzoulaki I, Riboli E, Kaaks R (2017) Added value of serum hormone measurements in risk prediction models for breast cancer for women not using exogenous hormones: results from the EPIC cohort. Clin Cancer Res 23(15):4181–4189. https://doi.org/10.1158/1078-0432.CCR-16-3011 PubMedCrossRef

62.

Key T, Appleby P, Barnes I, Reeves G, Endogenous H, Breast Cancer Collaborative G (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94(8):606–616PubMedCrossRef

63.

Thaler MA, Seifert-Klauss V, Luppa PB (2015) The biomarker sex hormone-binding globulin—from established applications to emerging trends in clinical medicine. Best Pract Res Clin Endocrinol Metab 29(5):749–760. https://doi.org/10.1016/j.beem.2015.06.005 PubMedCrossRef

64.

Hankinson SE, Willett WC, Manson JE, Colditz GA, Hunter DJ, Spiegelman D, Barbieri RL, Speizer FE (1998) Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 90(17):1292–1299PubMedCrossRef

65.

Fortunati N, Catalano MG, Boccuzzi G, Frairia R (2010) Sex hormone-binding globulin (SHBG), estradiol and breast cancer. Mol Cell Endocrinol 316(1):86–92. https://doi.org/10.1016/j.mce.2009.09.012 PubMedCrossRef

Titel: Determinants of prolactin in postmenopausal Chinese women in Singapore
verfasst von: Tiffany A. Katz
Anna H. Wu
Frank Z. Stanczyk
Renwei Wang
Woon-Puay Koh
Jian-Min Yuan
Steffi Oesterreich
Lesley M. Butler
Publikationsdatum: 09.11.2017
Verlag: Springer International Publishing
Erschienen in: Cancer Causes & Control / Ausgabe 1/2018
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-017-0978-8

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Determinants of prolactin in postmenopausal Chinese women in Singapore

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

A framework to understand diet, physical activity, body weight, and cancer risk

Early-onset baldness and the risk of aggressive prostate cancer: findings from a case–control study

Characterizing the neighborhood obesogenic environment in the Multiethnic Cohort: a multi-level infrastructure for cancer health disparities research

Uptake of HPV testing and extended cervical cancer screening intervals following cytology alone and Pap/HPV cotesting in women aged 30–65 years

Can we HIIT cancer if we attack inflammation?

Factors related to longitudinal adherence in colorectal cancer screening: qualitative research findings

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie